Answers are grounded in this paper and cite their sources.
With data presented herein, all primary and secondary study end points of SPARTAN were met; findings demonstrate the value of apalutamide as a treatment option for nonmetastatic castration-resistant prostate cancer.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: